Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Alopecia areata · Multiple myeloma

First Biotech (Australia)

Pfizer Australia Pty Ltd

First Biotech (Australia) trial registry — 126 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU HQ
2017 Founded
2 Employees
TGA registrant Type
Company details
Status
Public
HQ
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
Founded
2017
Employees
2
Programs
126
Drugs
208
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

First Biotech (Australia) clinical trials

Registry index of 126 ClinicalTrials.gov studies linked to First Biotech (Australia) programs — each row shows trial ID, program name, phase, status, and indication.

First Biotech (Australia) trial registry — 126 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for First Biotech (Australia).

  1. C4391010 — Phase 1

    Clinical update

  2. C4151006 — Phase 1

    Clinical update

  3. B7451015 — Phase 3

    Clinical update

  4. A Study to Learn If the Study Medicine Called... — Phase 1

    Clinical update

  5. C6461013 — Phase 2

    Clinical update

  6. C6081001 — Phase 1

    Clinical update

  7. C6001001 — Phase 1

    Clinical update

  8. C5951001 — Phase 1

    Clinical update

Trial registry

126 studies
  13. 2023-507757-15-01

    C3601010

    Phase 2 active small_molecule

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    CTIS ↗
  30. 2023-509179-18-00

    C2321001

    Phase 1 active other

    Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)

    CTIS ↗
  48. 2024-511128-15-00

    A8081075

    Approved active small_molecule

    This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

    CTIS ↗
  55. 2024-512120-11-00

    LETROZOLE, FULVESTRANT

    Phase 2 active small_molecule

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    CTIS ↗
  83. 2024-517756-35-00

    C5911001 - SGN-CD25V

    Phase 1 active other

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    CTIS ↗
  91. 2024-518696-65-00

    C4161006

    Phase 1 active other

    (HR) -positive human epidermal growth factor receptor 2 (HER2) -negative breast cancer (BC), non-small cell lung cancer (NSCLC), ovarian cancer, and triple negative breast cancer (TNBC)

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.